Matthew Powell, MD, discusses findings from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial of dostarlimab in combination with chemotherapy for patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.
In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.
In an interview with Targeted Oncology, David Peereboom, MD, discusses the correlation of immune activity to durable responses with VT1021 in patients with recurrent glioblastoma.
In an interview with Targeted Oncology, Mitul Gandhi, MD, reviewed the latest guideline recommendations for the workup and treatment of acute myeloid leukemia.
According to Bradley J. Monk, MD, FACS, FACOG, et al, multiple studies have shown the potential of tisotumab vedotin in patients with recurrent or metastatic cervical cancer. More evidence is needed before the oncology community can fully adopt its use.
Sia Daneshmand, MD on the non-muscle invasive bladder cancer treatment paradigm.
Yuri E. Nikiforov, MD, PhD, discusses improvements in diagnosis of thyroid cancer including the classification of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
In an interview with Targeted Oncology, Cyrus M. Khan, MD reviewed the recent FDA approvals is the chronic lymphocytic leukemia space. He also discusses other FDA decisions that have recently altered the landscape for the better.
In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.
During a Targeted Oncology Case-Based Roundtable event, Cristina Gasparetto, MD, discussed the case of a patient with stage I multiple myeloma and highlighted outcomes of the phase 3 BOSTON trial.
In an interview with Targeted Oncology, Warren C. Swegal, MD, takes a deep dive into the radioactive iodine-refectory differentiated thyroid cancer treatment armamentarium, and predicts the role of key agents in the near future.
Christina Fotopoulou, MD, PhD, discusses the results of the DUO-O trial in patients with newly diagnosed ovarian cancer.
Roby Thomas, MD, discusses the shortage of lutetium Lu 177 vipivotide tetraxetan, and how it had affected patients with metastatic castration-resistant prostate cancer being treated at UPMC Hillman Cancer Center.
Roby Thomas, MD discusses chemotherapy shortages and the impact these shortages have had on oncology research.
Ashwin Kishtagari, MD, discusses the adverse events of pacritinib for patients with primary myelofibrosis and low platelet counts.
In an interview, Rohan Garje, MD, discussed his research on comparing the outcomes of sarcomatoid and classic urothelial carcinoma of bladder.
In an interview with Targeted Oncology™, Q2 2023 Oncology Icons honoree, Thaddeus Beck, MD, FACP, discussed his 30 plus years of experience in clinical practice.
In an interview with Targeted Oncology, Ahmad Ozair, MBBS, discussed treatments for glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population.
In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the initial results of the addition of acalabrutinib to bendamustine and rituximab to treat patients with mantle cell lymphoma.
In an interview with Targeted Oncology, Hope S. Rugo, MD, explained the results of the phase 3 CAPItello-291 trial, and the potential impact of the study on the breast cancer treatment paradigm.
Frederick Locke, MD, discuss 2 allogeneic CD19-directed chimeric antigen receptor T-cell agents for the treatment of relapsed or refractory large B-cell lymphoma.
In an interview with Targeted Oncology, Lucia Masarova, MD, discussed the ongoing EXCEED-ET clinical trial and its potential to provide a new option to alter disease and ward off post-essential thrombocytopenia myelofibrosis in adult patients.
Tara Seery, MD, explains the next steps for the QUILT 88 study looking at a novel combination of therapies for patients with metastatic pancreatic cancer.
Hans C. Lee, MD, discusses the toxicity seen with the BCMA/CD3 bispecific antibody linvoseltamab for patients with relapsed/refractory multiple myeloma.
In an interview with Targeted Oncology, George Nahas, DO, discussed relevant research on chimeric antigen receptor therapy, bispecifics, and more that are moving the needle in multiple myeloma research.
Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.
Jeffrey Dome, MD, PhD, discusses how the use of atezolizumab has impacted the treatment of pediatric patients with alveolar soft part sarcoma.
Jonathan C. Trent, MD, PhD, discusses the molecular analyses of the INTRIGUE study, which was supported by Caris Life Science’s Precision Oncology Alliance, investigating patients with GIST that were presented at ASCO 2023.
Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.